Forecast Of The Day: Boston Scientific’s Revenue From Peripheral Interventions

+26.99%
Upside
40.15
Market
50.99
Trefis
BSX: Boston Scientific logo
BSX
Boston Scientific

What?

Boston Scientific’s (NYSE:BSX) Revenue from Peripheral Interventions rose from about $1.4 billion in 2019 to about $1.6 billion in 2020. Trefis expects the metric to rise to around $1.9 billion in 2021 and around $2.1 billion in 2022.

Why?

Relevant Articles
  1. What To Expect From Boston Scientific Stock Following Q1 Earnings?
  2. This Software Company Is Likely To Offer Better Returns Over Boston Scientific Stock
  3. Company Of The Day: Boston Scientific
  4. Is Boston Scientific Stock A Good Buy At $43?
  5. What To Expect From Boston Scientific Stock Following Q4 Earnings?
  6. Should You Buy Boston Scientific Stock Over Its Industry Peer?

We expect sales growth to be driven by product portfolio improvements and market factors, including the rising incidence of people suffering from Peripheral Vascular Diseases (PVD) and other conditions.

So What?

We think BSX stock is undervalued. We value BSX at about $50 per share, about 30% ahead of the current market price.

See Our Complete Analysis For Boston Scientific

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

Returns Nov 2021
MTD [1]
2021
YTD [1]
2017-21
Total [2]
BSX Return -11% 7% 78%
S&P 500 Return 1% 24% 108%
Trefis MS Portfolio Return -2% 48% 300%

[1] Month-to-date and year-to-date as of 11/30/2021
[2] Cumulative total returns since 2017

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates